Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

HCG (Human Chorionic Gonadotropin) peptide icon, one bubble per amino acidHCG (Human Chorionic Gonadotropin)20 residues (approx.)CPTMTRVLQGVLPALPQVVCEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.

HCG (Human Chorionic Gonadotropin)

Beginner tier: 250 IU, EOD · community consensus

Sexual HealthFDA Approved
33 h half-life·Injection

Also known as: HCG, hCG, Pregnyl

Just 250 IU every other day kept intratesticular testosterone at 93% of baseline in the Coviello 2005 trial (n=29)[1]. HCG is a glycoprotein hormone that mimics luteinizing hormone, and it's become the standard tool for preserving testicular function on TRT. The FDA approved it decades ago under brand names Pregnyl, Novarel, and Ovidrel. One complication: compounding pharmacies lost the right to produce HCG in March 2020 after BPCIA reclassification, pushing costs from $20 to $289 or more per vial. Men on testosterone replacement still reach for it because nothing else matches the evidence for preventing atrophy and protecting fertility.

What Is HCG (Human Chorionic Gonadotropin)?

HCG (human chorionic gonadotropin, CAS 9002-61-3) is a 36.7 kDa glycoprotein produced naturally during pregnancy that binds the same receptor as LH on Leydig cells. Coviello and colleagues settled the dose question in 2005 [1]: at 250 IU every other day, intratesticular testosterone dropped only 7% from baseline; at 500 IU EOD, it climbed 26% above baseline. Without HCG, intratesticular testosterone fell to near zero. It binds the same receptor as LH on Leydig cells, triggering testosterone synthesis through the cAMP signaling cascade. Think of it as a long-acting LH substitute that bypasses the pituitary entirely.

In practice, HCG sits at the center of two worlds. Fertility clinics use it under FDA-labeled indications for hypogonadotropic hypogonadism. TRT clinics prescribe it off-label to prevent testicular atrophy and maintain sperm production in men on exogenous testosterone. The community protocols at 250 to 500 IU every other day line up precisely with the published dose-response data.

The regulatory situation changed sharply in March 2020. On March 23, 2020, approved HCG applications were deemed biologics licenses under the BPCIA (FDA's deemed-BLA list). Brand-name Pregnyl or Novarel now runs about $289 per 10,000 IU vial at a discounted cash price, up from $20 to $40 when compounded versions were available. That cost shift pushed many US telehealth clinics toward gonadorelin as a compounded substitute, though no direct RCT proves gonadorelin matches HCG for intratesticular testosterone maintenance.

How HCG (Human Chorionic Gonadotropin) Works

HCG binds to the LH/CG receptor (LHCGR) on Leydig cells in the testes. That receptor activation triggers the cAMP second messenger cascade, which drives cholesterol into the steroidogenic pathway and produces testosterone. The same receptor sits on Sertoli cells indirectly supporting spermatogenesis through paracrine signaling.

What makes HCG useful during TRT is its ability to bypass the hypothalamic-pituitary axis completely. Exogenous testosterone shuts down the brain's GnRH pulse generator, which stops LH secretion. Leydig cells lose their signal, shrink, and stop producing testosterone locally. HCG replaces that missing LH signal at the gonadal level.

The glycoprotein's molecular weight (36.7 kDa) gives it a half-life of roughly 33 hours, confirmed by the Pregnyl FDA label and Rizkallah's pharmacokinetic work. Endogenous LH has a half-life of about 20 minutes. That difference is why 250 to 500 IU every other day provides steady Leydig cell stimulation; you don't need continuous infusion or daily dosing. Subcutaneous bioavailability sits around 95%, clinically equivalent to intramuscular injection. Peak levels arrive at approximately 12 to 20 hours after subcutaneous administration.

One limitation: HCG does not directly stimulate FSH receptors. Sertoli cell function depends on both testosterone (provided by HCG-stimulated Leydig cells) and FSH. In severe hypogonadotropic hypogonadism, HCG monotherapy produces sperm in about 78% of men, but adding exogenous FSH pushes outcomes higher (41 studies, n=1,673)[2].

HCG (Human Chorionic Gonadotropin) Benefits

  • HCG benefits center on testicular preservation, fertility maintenance, and hormonal support during testosterone replacement therapy.
  • Preserves intratesticular testosterone at 93% of baseline on just 250 IU every other day, per the Coviello 2005 dose-response study (n=29)[1].
  • Prevents testicular atrophy, the most consistently reported benefit across more than 2,000 threads on r/trt and r/Testosterone.
  • Maintains sperm production during TRT. Hsieh 2013 [3] tracked 26 men on concurrent TRT and 500 IU HCG every other day; zero developed azoospermia, and 9 achieved pregnancy.
  • FDA-approved with decades of clinical data supporting its safety profile, unlike most peptides on the market.
  • Real-world 2025 cohort data [4] confirmed 84 to 89% of anabolic steroid users showed sperm count improvement on similar HCG protocols, with median counts climbing from 18 million to 147 million.
  • Supports the full hormone cascade as an LH mimetic, maintaining downstream metabolites like estradiol that contribute to mood and sexual function.

HCG (Human Chorionic Gonadotropin): Science vs Community Consensus

Aligned
Scientific Evidence
Strong
Based on 10 key studies·FDA-approved

Strong evidence that HCG maintains intratesticular testosterone (ITT) during exogenous testosterone use and preserves spermatogenesis.

Dosing studied: 250-500 IU every other day (EOD) SC for TRT adjunct; 500-1,500 IU 3x/week SC for PCT; 500-1,000 IU 3x/week IM for hypogonadotropic hypogonadism (FDA label)
Read the evidence (key study, limitations)

Dose-response established: 250 IU EOD maintains ITT at ~93% of baseline; 500 IU EOD brings ITT ~26% above baseline. HCG + FSH combination superior to HCG monotherapy for restoring spermatogenesis in severe hypogonadotropic hypogonadism. FDA-approved for fertility indications with decades of clinical data.

Key Study

Coviello et al. 2005 (PMID 15713727): ITT dose-response in men on 200 mg/week testosterone enanthate; n=29. Confirmed: 250 IU EOD = -7% ITT vs baseline; 500 IU EOD = +26% ITT above baseline.

Limitations

Most TRT-adjunct ITT data from small trials. No large RCT comparing HCG to gonadorelin for ITT maintenance in TRT patients. Long-term Leydig desensitization threshold (>1,500 IU/injection) based on animal data and clinical inference, not prospective human RCT.

Community Experience
Strong
4.0/5
Based on ~2,000+ threads across r/trt, r/steroids, r/Testosterone

Widely regarded as the gold standard for testicular preservation and fertility maintenance on TRT.

Community dosing: 250-500 IU EOD SC is the dominant community standard; 500-1,000 IU 3x/week for active fertility; 1,500 IU 3x/week for PCT blast phase
Read the reports (what users report 4, common issues 5)

Community protocols closely mirror clinical data. Cost and availability since the March 2020 BPCIA transition are the dominant barriers; gonadorelin has largely replaced compounded HCG at US telehealth clinics.

What users report (4)
  • Prevents testicular atrophy: most consistently reported benefit across r/trt threads
  • Preserves fertility and sperm production during TRT
  • Maintains libido and sexual sensitivity during testosterone suppression
  • Some users report subjective wellbeing benefit attributed to intratesticular testosterone production
Common issues (5)
  • Elevated estradiol requiring AI management: most common complaint
  • Cost since the March 2020 BPCIA transition: Pregnyl/Novarel $289-$465/vial vs $20-40 for former compounded HCG
  • Acne and oily skin at doses above 500 IU
  • EOD injection frequency burdensome for some users
  • Some men remain azoospermic despite HCG: not universally effective for fertility
Science & Community Aligned

Community protocols at 250-500 IU EOD precisely match the Coviello 2005 dose-response data. PCT protocols align with 2026 clinical cohort data (PMID 41147237). No significant divergence between science and community on dosing or indication.

HCG (Human Chorionic Gonadotropin) Dosage Guide

CommunityTRT community standard: 250-500 IU SC every other day (r/trt, r/Testosterone). The aggressive tier, 1,000 IU 3x/week, sits inside the Pregnyl label range for hypogonadotropic hypogonadism (500-1,000 USP units 3x/week).Source (opens in a new tab)
LevelDose / InjectionFrequency
Beginner250 IU
Moderate500 IU
Aggressive1,000 IU
3x/weekTrack
Note:

Reconstitution math for a 5,000 IU vial with 2 mL bacteriostatic water: you get 2,500 IU per mL, or 250 IU per 10 units on a standard 100-unit insulin syringe. For 500 IU, draw to the 20-unit mark. For 1,500 IU (PCT dosing), that's 60 units.

Always use bacteriostatic water, not sterile water. Multi-dose vials need the benzyl alcohol preservative. Sterile water accelerates degradation fast after reconstitution.

Store reconstituted HCG refrigerated at 2 to 8 degrees Celsius and use within 60 days per the Pregnyl label. Lyophilized powder keeps at room temperature for up to 60 days or refrigerated for up to 2 years.

The thing most beginners miss: since March 23, 2020, FDA says HCG is not eligible for the 503A/503B compounding exemptions. If a telehealth clinic offers "compounded HCG," that product falls outside both exemptions. The discounted cash price for Pregnyl 10,000 IU runs roughly $289 at retail pharmacies. Check the NDC number on your vial to confirm it matches the Organon or Ferring product.

Cycling

Typically used continuously alongside TRT, not cycled. For PCT, 2-4 weeks is common. Doses above 1,500 IU per injection risk Leydig cell desensitization.

Calculate your HCG (Human Chorionic Gonadotropin) dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

HCG (Human Chorionic Gonadotropin) Protocols by Goal

beginnerCommunityContinuous alongside TRT
Continuous TRT adjunct
Wk Continuous with TRT
250 IU · Every other day (EOD) · Subcutaneous

Expected: Testicular volume maintained or improved. ITT preserved at ~93% of baseline vs near-zero suppression without HCG. Minimal E2 elevation at 250 IU for most men: AI often not required.

Monitor: Check estradiol (E2) at 4-6 weeks after starting. Many men do not need an AI at 250 IU EOD. No semen analysis required unless fertility is a goal.

How to Use HCG (Human Chorionic Gonadotropin)

  1. 1
    Step 1

    Gather your supplies: HCG vial (5,000 IU or 10,000 IU), bacteriostatic water, a mixing syringe, and a 29 to 31 gauge insulin syringe (0.5 mL or 1 mL).

  2. 2
    Reconstitute the vial

    For a 5,000 IU vial, inject 2 mL of bacteriostatic water slowly down the side of the vial. Swirl gently until dissolved. Do not shake.

  3. 3
    Draw your dose using a 100-unit insulin syringe

    At 2,500 IU per mL concentration: 10 units on the syringe equals 250 IU; 20 units equals 500 IU; 60 units equals 1,500 IU.

  4. 4
    Clean the injection site with an alcohol swab

    Subcutaneous injection into abdominal fat is preferred by most TRT clinics. Pinch a fold of skin, insert the needle at a 45 to 90 degree angle, inject slowly, release the pinch.

  5. 5
    Step 5

    Rotate injection sites across the abdomen, alternating sides. Thigh and upper arm are acceptable alternatives.

  6. 6
    Cap the vial, return it to the refrigerator immediately

    Date the vial on reconstitution day. Discard after 60 days.

  7. 7
    Typical frequency is every other day for TRT adjunct use

    Space injections evenly across the week (Monday, Wednesday, Friday works for 3x/week PCT protocols).

Alternative Routes

Subcutaneous (SC)

No dose adjustment: SC bioavailability ~95%, clinically equivalent to IM

More comfortable; easier to self-administer; less post-injection soreness. Abdominal fat, thigh, or upper arm acceptable sites. Tmax slightly delayed vs IM (~12 hours SC vs ~6 hours IM per Pregnyl label), not clinically relevant for EOD or 3x/week TRT dosing. Use 29-31G insulin syringe, 4-8mm needle.

Intramuscular (IM)

Same dose as SC; no adjustment needed

FDA label specifies IM for all labeled indications. Tmax ~6 hours IM per Pregnyl label. More painful than SC. Deltoid or gluteal sites. More common in clinical fertility protocols; SC broadly substituted in TRT practice.

Mixing your own vial? Use the HCG (Human Chorionic Gonadotropin) reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

HCG (Human Chorionic Gonadotropin) Stacking Protocols

Works With

Avoid

GnRH agonists (leuprolide, buserelin, triptorelin): continuous use

Continuous GnRH agonist use causes LH/FSH suppression via pituitary receptor downregulation, directly opposing HCG's LH-mimetic effect on Leydig cells. Combination is physiologically counterproductive.

Do not combine
GnRH antagonists (cetrorelix, ganirelix)

Blocks pituitary GnRH receptors, suppressing endogenous LH/FSH. While HCG bypasses the pituitary, combining with GnRH antagonists creates unpredictable hormonal disruption without clear therapeutic rationale outside closely supervised fertility protocols.

Estimated Cost

Brand Price
Pregnyl 10,000 IU: ~$289 discounted cash price / ~$427-$465 retail (Organon). Novarel 10,000 IU: ~$289 discounted cash price / ~$432 retail (Ferring). Ovidrel 250 mcg prefilled syringe: ~$107-$235 discounted cash price (single-use fertility trigger format: not suitable for TRT EOD protocols).
Compounded
Not eligible for the 503A/503B compounding exemptions since March 23, 2020, when HCG became a licensed biologic (FDA notice to compounders). Gonadorelin (~$30-50/month compounded) is the common domestic substitute.

Pricing updated 2026-04-09

HCG (Human Chorionic Gonadotropin) Side Effects

Raised estradiol is the primary management challenge with HCG. The mechanism is straightforward: HCG stimulates Leydig cells to produce testosterone, and aromatase converts a portion of that testosterone to estradiol. Men with higher body fat or genetic aromatase polymorphisms are more susceptible. At 250 IU every other day, most men manage without an aromatase inhibitor. At 500 IU and above, symptomatic estradiol elevation becomes common enough that labs at 4 to 6 weeks are standard practice.

Water retention and bloating follow from estradiol elevation and tend to appear at moderate to high doses. Gynecomastia risk exists if estrogen climbs unchecked, particularly in men already prone to breast tissue sensitivity. Nipple tenderness or puffiness warrants bloodwork, not panic.

Leydig cell desensitization is the risk that gets less attention but matters most over time. Chronic dosing above 1,500 IU per injection can downregulate LHCGR expression on Leydig cells, reducing their responsiveness to both HCG and endogenous LH. This threshold comes from animal data and clinical inference rather than a prospective human RCT, but it's the reason every experienced protocol caps individual injections at 1,500 IU. Signs include declining testicular volume despite continued use and loss of the estradiol elevation you'd expect at a given dose.

Injection site reactions are typical for both intramuscular and subcutaneous administration. Pain, redness, and mild swelling at the injection site affect a subset of users. Rotating sites and using 29 to 31 gauge insulin needles minimizes discomfort.

Acne and oily skin show up in community reports at doses above 500 IU, consistent with the higher intratesticular testosterone production at those levels.

Headache and irritability appear in clinical literature and user reports without a clear dose-response pattern.

Not everyone responds to HCG for fertility. Some men remain azoospermic despite adequate dosing; HCG targets Leydig cells but doesn't directly stimulate Sertoli cells. FSH addition is the standard next step for non-responders [2].

When to stop or seek medical evaluation: persistent gynecomastia symptoms, hematocrit above 52%, signs of Leydig desensitization (declining response at stable dose), or any allergic reaction. Contraindicated in hormone-sensitive cancers (prostate, breast), precocious puberty, and pregnancy unless under direct fertility specialist supervision.

Common Issues & Solutions

Estradiol rising after HCG: HCG drives Leydig cell testosterone production, which aromatizes to E2. Test E2 at 4-6 weeks; add anastrozole 0.25-0.5 mg or exemestane 12.5 mg on injection days only if confirmed elevated and symptomatic. Do not add AI preemptively without labs.

Testicular volume not recovering after 3 months: Increase from 250 IU to 500 IU EOD. For active fertility, 500 IU EOD is the minimum evidence-backed dose (Hsieh 2013). If still insufficient at 6 months, add FSH (Gonal-F or Follistim): HCG drives testosterone but FSH is required for full Sertoli cell support and spermatogenesis.

Azoospermia persisting despite HCG: HCG targets Leydig cells (testosterone) but not Sertoli cells directly. FSH is required for full spermatogenesis. Add FSH stimulation per specialist; PMID 39445789 meta-analysis confirms HCG + FSH combination superior to HCG alone for sperm output in hypogonadotropic hypogonadism.

Cost and supply since March 23, 2020: HCG is not eligible for the 503A/503B compounding exemptions (FDA). Brand-name Pregnyl/Novarel ~$289 discounted cash price. Consider gonadorelin (compounded, ~$30-50/month) as a cost-accessible alternative: note no direct RCT proving ITT equivalence to HCG for TRT adjunct.

Using sterile water instead of bacteriostatic water: Multi-dose vials require bacteriostatic water (0.9% benzyl alcohol preservative). Sterile water has no preservative and significantly accelerates degradation after reconstitution. Always use bac water for HCG vials.

Ask AI about this page

Ask AI for a second opinion on HCG (Human Chorionic Gonadotropin) dosing and side effects

Contraindications

  • Pregnancy (unless under direct fertility specialist supervision)
  • Hormone-sensitive cancers (prostate, breast)
  • Precocious puberty
  • Known hypersensitivity to HCG
  • Androgen-dependent neoplasm

Drug Interactions

  • Aromatase inhibitors (commonly co-prescribed to manage estradiol)
  • Exogenous testosterone (standard combination in TRT fertility protocols)
  • SERMs like clomiphene (sometimes stacked in PCT)
  • GnRH agonists/antagonists (opposing mechanisms: avoid combining)
  • Continuous GnRH agonist use causes LH/FSH suppression via pituitary receptor downregulation, directly opposing HCG's LH-mimetic effect on Leydig cells. Combination is physiologically counterproductive.

Product Quality

Recommended Monitoring

TestWhenTarget
Estradiol (E2): sensitive LC-MS/MS assay preferredBaseline before starting HCG; repeat at 4-6 weeks; every 3 months ongoingSymptomatic threshold varies by individual; many men tolerate up to 40-50 pg/mL; treat based on symptoms + labs, not labs alone
Total and free testosteroneRoutine TRT monitoring schedule; baseline before HCG additionNot listed
Semen analysisBaseline (if fertility is goal); at 3 months and 6 months on HCGWHO 2021 reference: >16M/mL concentration, >42% motility, >4% normal morphology (Kruger strict)
LH and FSHBaseline; primarily useful post-TRT during PCT to track HPG axis recovery. Not useful during active TRT (will be suppressed).Not listed
Hematocrit / CBCEvery 6 months on TRT + HCGHematocrit <52% (men)
Estradiol (E2): sensitive LC-MS/MS assay preferred

HCG stimulates Leydig cell testosterone production, which aromatizes to E2 via aromatase. E2 elevation is the most common management issue on HCG.

Total and free testosterone

HCG may elevate total T above TRT target at higher doses: informs TRT dose adjustments.

Semen analysis

Only objective measure of spermatogenesis response. Identifies non-responders requiring FSH addition.

LH and FSH

Post-TRT, LH and FSH recovery confirms HPG axis normalization. Useful to time SERM tapering in PCT.

Hematocrit / CBC

HCG-stimulated intratesticular testosterone production may contribute to erythrocytosis on top of TRT-driven erythropoiesis.

HCG (Human Chorionic Gonadotropin) Before and After

Week 1-2

LH receptor activation begins. Intratesticular testosterone rises. Some men notice improved testicular fullness.

Week 3-4

Testicular volume stabilizes or increases. Sperm parameters begin improving.

Week 6-8

Full effect on intratesticular testosterone. Semen analysis may show improvement.

Month 3-6

Spermatogenesis typically restored. Fertility potential significantly improved vs TRT-only.

What to Expect

Week 1 to 2: LH receptor activation and early ITT rise. HCG binds LHCGR on Leydig cells within hours. Intratesticular testosterone starts climbing within days. Many users report subjective testicular fullness in the first week; some notice improved mood or libido that could be ITT-driven or placebo. Mild injection site reactions are common. Estradiol elevation begins, check labs at week 4.

Week 3 to 4: Testicular volume increases and sperm production begins responding to restored ITT levels. Atrophy visibly reverses for most men. Estradiol-related symptoms (water retention, nipple sensitivity) may appear in men with higher aromatase activity. Anastrozole or exemestane gets added based on lab confirmation at this stage.

Week 6 to 8: ITT plateau reached for your dosing tier. Early semen analysis improvement is possible. Testicular size is subjectively "back to normal" for most users on community forums. Libido and sexual sensitivity hold steady. AI dosing typically stabilizes by this window. Acne may appear at higher doses (500 to 1,000 IU).

Month 3 to 6: Spermatogenesis confirmed in the majority of men on 500 IU every other day. Hsieh 2013 [3] recorded 9 out of 26 pregnancies by month 6 on HCG plus TRT. Real-world 2025 cohort data [4] showed median sperm counts jumping from 18 million to 147 million, with an 84% improvement rate and 6 pregnancies during the study period. Non-responders with persistent azoospermia typically add FSH at this point.

PCT Month 3 to 12: HPG axis normalization after anabolic steroid use. A 2026 cohort (n=79)[5] confirmed 87.5% normozoospermia at 12 months with HCG 1,500 IU 3x/week plus clomiphene, compared to 69.2% with clomiphene alone and 58.6% with no treatment. Testicular volume increased 20% or more in 70.8% of combined-therapy patients. Recovery runs slower after longer or heavier AAS cycles. Men who used concurrent HCG during their cycle recover faster in PCT.

Detailed Timeline: Science vs Community

Week 1-2
Science

HCG binds LHCGR on Leydig cells within hours of injection. ITT begins rising within days. cAMP cascade initiated; steroidogenesis increases.

Community

Subjective testicular fullness reported within first week by many users. Some report improved mood or libido: possibly ITT-driven, possibly placebo.

Week 3-4
Science

Testicular volume measurably increases. Spermatogenesis begins responding to restored ITT levels. Scrotal fullness returns.

Community

Testicular fullness consistently reported. Atrophy visibly reversing. E2-related symptoms (water retention, nipple sensitivity) may appear in men with higher aromatase activity.

Week 6-8
Science

ITT plateau reached per dosing tier. Early semen analysis improvement possible. Hsieh 2013 data: significant sperm parameter improvement measurable by month 3.

Community

Testicular size subjectively "back to normal" for most. Libido and sexual sensitivity maintained. AI dosing typically stabilizes by week 6-8.

Month 3-6
Science

Spermatogenesis restored in majority on 500 IU EOD. Hsieh 2013 (PMID 23260550): 9/26 pregnancies by month 6 on HCG + TRT. Real-world 2025 cohort (PMID 40620361): median sperm count 18M → 147M; 84% improvement rate; 6 pregnancies during study.

Community

Fertility success frequently reported at 3-6 month mark. Non-responders (azoospermia persisting) noted: prompts FSH addition discussion.

PCT Month 3-12
Science

PMID 41147237 (2026): 87.5% normozoospermia at 12 months with HCG + SERM. PMID 38399562 (2024): ~96% spermatogenesis restoration within 12 months post-TRT with combined protocol. Testicular volume ≥20% increase in 70.8% of combined-therapy patients.

Community

Recovery slower after longer or heavier AAS cycles. Men who ran concurrent HCG during cycle recover significantly faster in PCT. HCG blast before SERM-only PCT is common community practice.

Pharmacokinetics

Half-Life
33h
Bioavailability
SC: ~95%, IM: ~95%
Tmax
~20 hours (IM), ~12-20 hours (SC)
Data Confidence
high

Source: Pregnyl FDA label; confirmed by Rizkallah et al.

Pharmacokinetics: Active Dose Over Time

t½ = ~33 hours

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
20
Sequence
CPTMTRVLQGVLPALPQVVC
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: 9002-61-3

Who Should Consider HCG (Human Chorionic Gonadotropin)

  • Men on TRT wanting to preserve fertility
  • Men experiencing testicular atrophy from testosterone use
  • Couples undergoing fertility treatment
  • Men in post-cycle therapy (PCT)

Related Peptides

What Changed for HCG (Human Chorionic Gonadotropin)

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 202610 Citations

References

  1. [1]Low-dose HCG maintains intratesticular testosterone in men with testosterone-induced gonadotropin suppression (opens in a new tab)(n=29)PubMed (opens in a new tab)PubMed
  2. [2]Efficacy of gonadotropin treatment for induction of spermatogenesis in men with pathologic gonadotropin deficiency: a meta-analysis (Muir et al., Clin Endocrinol 2025) (opens in a new tab)(n=1,673)PubMed (opens in a new tab)PubMed
  3. [3]Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy (J Urol 2013) (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]Efficacy of human chorionic gonadotropin hormone in restoring spermatogenesis in men using non-prescribed androgens: a retrospective analysis of real-world data (F S Rep 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
  5. [5]Post-cycle therapy after short-term anabolic-androgenic steroid use (BJU Int 2026) (opens in a new tab)(n=79)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Room temperature up to 60 days, refrigerated up to 2 years
After Reconstitution
Refrigerate at 2-8°C, use within 60 days (per Pregnyl label)
Temperature
2-8°C (36-46°F) after reconstitution

Frequently Asked Questions

HCG stimulates Leydig cells to produce testosterone, and some of that testosterone converts to estradiol via aromatase; same pathway as exogenous testosterone. At doses of 250-500 IU every other day, many men manage fine without an aromatase inhibitor. If you carry more body fat or have genetic factors that increase aromatase activity, low-dose anastrozole (0.25-0.5 mg) may help. Always test estradiol before automatically adding an AI.

HCG (Human Chorionic Gonadotropin) dosing varies by experience level. Beginners typically start at 250 IU eod, moderate users at 500 IU eod, and aggressive protocols use 1,000 IU 3x/week.

HCG (Human Chorionic Gonadotropin) typically comes in 5000IU or 10000IU vials. Add 2mL of bacteriostatic water to the vial. Use the free calculator for exact syringe units based on your desired dose.

The half-life of HCG (Human Chorionic Gonadotropin) is ~33 hours. This determines how frequently you need to dose for consistent blood levels.

Raised estradiol is the primary management challenge with HCG. The mechanism is straightforward: HCG stimulates Leydig cells to produce testosterone, and aromatase converts a portion of that testosterone to estradiol. Men with higher body fat or genetic aromatase polymorphisms are more susceptible. At 250 IU every other day, most men manage without an aromatase inhibitor. At 500 IU and above, symptomatic estradiol elevation becomes common enough that labs at 4 to 6 weeks are standard practice. Water retention and bloating follow from estradiol elevation and tend to appear at moderate to high doses. Gynecomastia risk exists if estrogen climbs unchecked, particularly in men already prone to breast tissue sensitivity. Nipple tenderness or puffiness warrants bloodwork, not panic. Leydig cell desensitization is the risk that gets less attention but matters most over time. Chronic dosing above 1,500 IU per injection can downregulate LHCGR expression on Leydig cells, reducing their responsiveness to both HCG and endogenous LH. This threshold comes from animal data and clinical inference rather than a prospective human RCT, but it's the reason every experienced protocol caps individual injections at 1,500 IU. Signs include declining testicular volume despite continued use and loss of the estradiol elevation you'd expect at a given dose. Injection site reactions are typical for both intramuscular and subcutaneous administration. Pain, redness, and mild swelling at the injection site affect a subset of users. Rotating sites and using 29 to 31 gauge insulin needles minimizes discomfort. Acne and oily skin show up in community reports at doses above 500 IU, consistent with the higher intratesticular testosterone production at those levels. Headache and irritability appear in clinical literature and user reports without a clear dose-response pattern. Not everyone responds to HCG for fertility. Some men remain azoospermic despite adequate dosing; HCG targets Leydig cells but doesn't directly stimulate Sertoli cells. FSH addition is the standard next step for non-responders (PMID 39445789). When to stop or seek medical evaluation: persistent gynecomastia symptoms, hematocrit above 52%, signs of Leydig desensitization (declining response at stable dose), or any allergic reaction. Contraindicated in hormone-sensitive cancers (prostate, breast), precocious puberty, and pregnancy unless under direct fertility specialist supervision.